SCYNEXIS Inc. (SCYX)
SCYX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1178253/000117825326000007/0001178253-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SCYX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001178253 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $20.6M |
| Net income | -$8.6M |
| Operating income | -$16.1M |
| Net margin | -41.8% |
| Operating margin | -78.0% |
| Revenue growth | +449.9% |
| Cash | $21.3M |
| Total assets | $59.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $8.2M cash; operating cash flow -$3.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 9,953,155 (2026-11-01); 41,965,058 a year earlier; 37,207,799 three years earlier. 1y figure adjusted for splits (1-for-8 overall); 3y figure adjusted for splits (1-for-8 overall). | Cover page 2026-11-01 |
| Reverse splits, 3 years | 1; latest 1-for-8 on 2026-06-01 | Source 2026-06-01 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Morristown, New Jersey, United States | PCAOB Form AP 2026-03-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$8.5M | -$7.5M | $8.2M | No debt tags | $18.9M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $235K | $7.4M | -$14.9M | $10.5M | No debt tags | $19.2M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $0 | -$21.3M | -$8.1M | $36.7M | No debt tags | $20.3M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $18.6M | $12.3M | $18.4M | $21.3M | No debt tags | $20.6M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $334K | -$8.6M | -$8.7M | $14.8M | No debt tags | $2.9M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $1.4M | -$6.9M | -$7.5M | $11.0M | No debt tags | $3.3M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $257K | -$5.4M | -$7.5M | $6.9M | No debt tags | $2.6M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $977K | -$4.4M | -$9.9M | $16.1M | No debt tags | $3.7M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-05 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-09-28 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 744 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.3% |
| 1 month | -19.5% |
| 3 months | -37.3% |
| Year to date | -36.5% |
| 1 year | -32.0% |
| From 52-week high | -63.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| NXTC | NextCure Inc. | $6.68 | +4.38% | $30.6M |
| NSRX | Nasus Pharma Ltd. | $2.66 | -7.32% | $31.2M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier